ALKS-8700(CAT: I006496) is an investigational drug that is being developed by Alkermes as a potential treatment for multiple sclerosis (MS). It is an oral prodrug of monomethyl fumarate (MMF), which is the active metabolite of dimethyl fumarate (DMF), a drug that is currently approved for the treatment of MS. ALKS-8700 is designed to offer a more convenient dosing regimen and potentially lower gastrointestinal side effects compared to DMF. It works by activating the nuclear factor erythroid-derived 2-like 2 (Nrf2) pathway, which leads to the upregulation of antioxidant and anti-inflammatory genes, ultimately reducing the neuroinflammation that is associated with MS. ALKS-8700 has completed several clinical trials, and the results have been promising.
| Catalog Number | I006496 |
| CAS Number | 1577222-14-0 |
| Synonyms | Diroximel fumarate; ALKS8700; ALKS 8700; ALKS-8700;2-(2,5-dioxopyrrolidin-1-yl)ethyl methyl fumarate |
| Molecular Formula | C11H13NO6 |
| Purity | 95% |
| Solubility | Soluble in DMSO |
| Storage | 0 - 4°C for short term or -20 °C for long term |
| IUPAC Name | 4-O-[2-(2,5-dioxopyrrolidin-1-yl)ethyl] 1-O-methyl (E)-but-2-enedioate |
| InChI | InChI=1S/C11H13NO6/c1-17-10(15)4-5-11(16)18-7-6-12-8(13)2-3-9(12)14/h4-5H,2-3,6-7H2,1H3/b5-4+ |
| InChIKey | YIMYDTCOUQIDMT-SNAWJCMRSA-N |
| SMILES | COC(=O)C=CC(=O)OCCN1C(=O)CCC1=O |
